Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 10, 2010, Pages 1009-1018

  Yoo, A Rum ^a   Koh, Seong Ho ^a   Cho, Goang Won ^a   Kim, Seung H ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Anti proliferation; Atherosclerosis; cAMP; Cilostazol; ERK

Indexed keywords

CILOSTAZOL; GLYCOGEN SYNTHASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN;

ARTICLE; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 78249237183     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.4309     Document Type: Article

References (41)

1. Dzau VJ, Braun-Dullaeus RC, Sedding DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med, 2002; 8: 1249-1256
2. Schwartz SM, Heimark RL, Majesky MW: Developmental mechanisms underlying pathology of arteries. Physiol Rev, 1990; 70: 1177-1209
3. Ishizaka N, Taguchi J, Kimura Y, Ikari Y, Aizawa T, Togo M, Miki K, Kurokawa K, Ohno M: Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis, 1999; 142: 41-46
4. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, Saitoh Y: Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther, 1979; 211: 26-30
5. Kim MJ, Park KG, Lee KM, Kim HS, Kim SY, Kim CS, Lee SL, Chang YC, Park JY, Lee KU, Lee IK: Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension, 2005; 45: 552-556
6. Ito C, Kusano E, Akimoto T, Takeda S, Sasaki N, Umino T, Iimura O, Ando Y, Asano Y: Cilostazol enhances IL-1beta-induced NO production and apoptosis in rat vascular smooth muscle via PKA-dependent pathway. Cell Signal, 2002; 14: 625-632
7. Lee SY, Kang MJ, Cha JK: Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke. J Clin Neurol, 2008; 4: 148-152
8. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol, 1997; 9: 180-186
9. Fisher M, Liu B, Glennon PE, Southgate KM, Sale EM, Sale GJ, Lewis MJ, Groves PH: Downregulation of the ERK 1 and 2 mitogen activated protein kinases using antisense oligonucleotides inhibits proliferation of porcine vascular smooth muscle cells. Atherosclerosis, 2001; 156: 289-295
10. Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT, Lin CC: Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol, 2001; 132: 1531-1541
11. Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov, 2007; 6: 821-833
12. Hayashi K, Takahashi M, Kimura K, Nishida W, Saga H, Sobue K: Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J Cell Biol, 1999; 145: 727-740
13. Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, Sobue K: Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulinlike growth factor-I signaling in vascular smooth muscle cells. J Biol Chem, 2004; 279: 40807-40818
14. Koh SH, Noh MY, Cho GW, Kim KS, Kim SH: Erythropoietin increases the motility of human bone marrowmultipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev, 2009; 18: 411-421
15. Smith-Mungo L, Kagan HM: PKC-MEK-MAPK-dependent signal transduction pathway mediates the stimulation of lysyl oxidase expression by serum and PDGF in rat aortic smooth muscle cells. J Cell Biochem, 2002; 85: 775-784
16. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, Aoki M, Yamamoto K, Higaki J, Ogihara T: Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension, 2000; 35: 237-243
17. Mori D, Ishii H, Kojima C, Nitta N, Nakajima K, Yoshida M: Cilostazol inhibits monocytic cell adhesion to vascular endothelium via upregulation of cAMP. J Atheroscler Thromb, 2007; 14: 213-218
18. Zhao H, Quilley J, Montrose DC, Rajagopalan S, Guan Q, Smith CJ: Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty. Am J Physiol Heart Circ Physiol, 2007, 292: H2973-2981
19. Qiao J, Huang F, Lum H: PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol, 2003; 284: L972-980
20. Fang Y, Olah ME: Cyclic AMP-dependent, protein kinase A-independent activation of extracellular signal-regulated kinase 1/2 following adenosine receptor stimulation in human umbilical vein endothelial cells: role of exchange protein activated by cAMP 1 (Epac1). J Pharmacol Exp Ther, 2007; 322: 1189-1200
21. Hong KW, Kim KY, Shin HK, Lee JH, Choi JM, Kwak YG, Kim CD, Lee WS, Rhim BY: Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/ cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther, 2003; 306: 1182-1190
22. Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, Kwak YG, Kim KY, Hong KW: Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMPdependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther, 2006; 317: 1238-1245
23. Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, Okouchi M, Itoh M: Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res, 2004; 68: 119-125
24. Hashimoto A, Miyakoda G, Hirose Y, Mori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis, 2006: 189: 350-357
25. Winkles JA, Gay CG: Serum, phorbol ester, and polypeptide mitogens increase class 1 and 2 heparin-binding (acidic and basic fibroblast) growth factor gene expression in human vascular smooth muscle cells. Cell Growth Differ, 1991; 2: 531-540
26. Dumaz N, Marais R: Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem, 2003; 278: 29819-29823
27. Hafner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A, Pippig S, Lohse M, Ueffing M, Kolch W: Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol, 1994; 14: 6696-6703
28. Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A: Integrin regulation of cell signalling and motility. Biochem Soc Trans, 2004; 32: 443-446
29. Ross R, Glomset JA: Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science, 1973; 180: 1332-1339
30. Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen- activated protein kinase cascade for the treatment of cancer. Oncogene, 2007; 26: 3291-3310
31. Lewis TS, Shapiro PS, Ahn NG: Signal transductionthrough MAP kinase cascades. Adv Cancer Res, 1998; 74: 49-139
32. Lee JH, Johnson PR, Roth M, Hunt NH, Black JL: ERK activation and mitogenesis in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2001; 280: L1019-1029
33. Koyama H, Olson NE, Dastvan FF, Reidy MA: Cell replication in the arterial wall: activation of signaling pathway following in vivo injury. Circ Res, 1998; 82: 713-721
34. Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK: Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Biol Cell, 1999; 10:3197-3204
35. Cospedal R, Lobo M, Zachary I: Differential regulation of extracellular signal-regulated protein kinases (ERKs) 1 and 2 by cAMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells. Biochem J, 1999; 342 (Pt 2): 407-414
36. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW: Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science, 1993; 262: 1065-1069
37. Cook SJ, McCormick F: Inhibition by cAMP of Ras-dependent activation of Raf. Science, 1993; 262: 1069-1072
38. Inada H, Shindo H, Tawata M, Onaya T: Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY5Y human neuroblastoma cells. Life Sci, 1999; 65: 1413-1422
39. Munoz B, Huerta M, Lopez-Bayghen E: Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells. Eur J Pharmacol, 2009; 616: 22-30
40. Lawlor MA, Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci, 2001; 114: 2903-2910
41. Lee KM, Lee HJ, Kim MK, Kim HS, Jung GS, Hur SH, Kim HT, Cho WH, Kim JG, Kim BW, Lim JO, Choi HS, Lee KU, Park KG, Lee IK: Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. Atherosclerosis, 2009; 207: 391-398